866-997-4948(US-Canada Toll Free)

Kidney Transplant Rejection - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 148 Pages

Kidney Transplant Rejection - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Kidney Transplant Rejection - Overview 7
Kidney Transplant Rejection - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Kidney Transplant Rejection - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Kidney Transplant Rejection - Companies Involved in Therapeutics Development 24
Amgen Inc 24
Angion Biomedica Corp 24
Apellis Pharmaceuticals Inc 25
Astellas Pharma Inc 25
Biogen Inc 26
Catalyst Biosciences Inc 26
Corline Biomedical AB 27
CSL Ltd 27
GlaxoSmithKline Plc 28
Grifols SA 28
Hansa Medical AB 29
Kyowa Hakko Kirin Co Ltd 29
Magnus Life Ltd 30
Noorik Biopharmaceuticals AG 30
Novartis AG 31
Opsona Therapeutics Ltd 31
OSE Immunotherapeutics 32
Pharmicell Co Ltd 32
Pharming Group NV 33
Prolong Pharmaceuticals LLC 33
Quark Pharmaceuticals Inc 34
Shire Plc 34
Tiziana Life Sciences Plc 35
Kidney Transplant Rejection - Drug Profiles 36
albumin (human) - Drug Profile 36
ambrisentan - Drug Profile 37
AMY-101 - Drug Profile 38
APL-2 - Drug Profile 40
AS-2521780 - Drug Profile 43
ASP-0028 - Drug Profile 44
basiliximab biobetter - Drug Profile 45
BB-3 - Drug Profile 46
belimumab - Drug Profile 50
bleselumab - Drug Profile 57
C1 esterase inhibitor (human) - Drug Profile 59
C1 esterase inhibitor (human) - Drug Profile 64
C1 esterase inhibitor (recombinant) - Drug Profile 67
carfilzomib - Drug Profile 74
CB-2782 - Drug Profile 86
Cellgram for Kidney Transplant Rejection - Drug Profile 87
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 88
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 89
Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 90
CFZ-533 - Drug Profile 91
foralumab - Drug Profile 93
FR-104 - Drug Profile 95
FX-06 - Drug Profile 98
GSK-1070806 - Drug Profile 100
HBI-002 - Drug Profile 101
HBI-137 - Drug Profile 102
lefluonomide - Drug Profile 103
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 104
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 106
MRX-109 - Drug Profile 107
OPN-305 - Drug Profile 108
QPI-1002 - Drug Profile 111
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 114
Renaparin - Drug Profile 119
rituximab - Drug Profile 120
Sanguinate - Drug Profile 126
tiomolibdate diammonium - Drug Profile 129
TNT-009 - Drug Profile 130
Kidney Transplant Rejection - Dormant Projects 133
Kidney Transplant Rejection - Discontinued Products 135
Kidney Transplant Rejection - Product Development Milestones 136
Featured News & Press Releases 136
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 145
Disclaimer 146

List of Tables
Number of Products under Development for Kidney Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kidney Transplant Rejection - Pipeline by Amgen Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp, H1 2017
Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Biogen Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Corline Biomedical AB, H1 2017
Kidney Transplant Rejection - Pipeline by CSL Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2017
Kidney Transplant Rejection - Pipeline by Grifols SA, H1 2017
Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H1 2017
Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Magnus Life Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H1 2017
Kidney Transplant Rejection - Pipeline by Novartis AG, H1 2017
Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics, H1 2017
Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Pharming Group NV, H1 2017
Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Shire Plc, H1 2017
Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc, H1 2017
Kidney Transplant Rejection - Dormant Projects, H1 2017
Kidney Transplant Rejection - Dormant Projects, H1 2017 (Contd..1), H1 2017
Kidney Transplant Rejection - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Kidney Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *